Policy & Regulation
IACTA Pharmaceuticals Names Bahl as Chief Financial Officer, Carter as Chief Medical Officer
28 July 2021 - - US-based ophthalmic therapeutics company IACTA Pharmaceuticals, Inc. (IACTA) has appointed Yogesh Bahl as chief financial officer and Eric Carter, M.D., Ph.D., as chief medical officer, the company said.

Yogesh Bahl brings over 25 years of pharmaceutical experience in strategy, finance, accounting, audit, and risk management.

Bahl previously served as managing director at AlixPartners, a global professional services firm where he co-led the Healthcare and Life Sciences practice, improving operations and profitability, serving as a financial expert, and conducting due diligence for private equity firms and corporations.

Additionally, he was a leader of the firm's Diversity and Inclusion efforts.

Prior to AlixPartners, Bahl served as a partner in the financial advisory business at Deloitte, where he worked from 1997-2014 and led the US Life Sciences practice of that business for three years.

At Deloitte, he worked with pharmaceutical companies of all sizes to conduct financial audits, perform investigations, improve compliance programs, manage corporate transactions, analyze commercial operations, and evaluate supply chain integrity.

Bahl holds an MBA in finance and statistics and a bachelor's degree in accounting and international business from New York University's Stern School of Business. He is a certified public accountant in the State of New York.

Eric Carter, M.D., Ph.D. has over 20 years of experience as both a physician and pharmaceutical industry executive, specializing in research and development as well as commercialization across multiple therapeutic areas.

Dr. Carter previously served as senior vice president, chief medical officer, Global Head of Clinical and Non-clinical Development of Allergan, Inc. from 2011 through its acquisition by Actavis Pharmaceuticals in 2015, where he led preclinical and global clinical development and operations in ophthalmology, dermatology, urology, CNS, and plastic surgery. Dr. Carter led Allergan through 11 drug candidate approvals during his tenure.

Prior to Allergan, Dr. Carter served as chief science officer, Head of R and D and Chief Medical officer of King Pharmaceuticals from 2007 until the company was acquired by Pfizer in 2011.

Prior to King, Dr. Carter worked for Glaxo Wellcome and GSK where he held positions of increasing responsibility in global clinical development and medical affairs.

Dr. Carter began his medical career at the University of North Carolina, Chapel Hill where he held board certifications in Internal Medicine, Gastroenterology and Hepatology and Clinical Nutrition.

Dr. Carter currently serves as chairman of the Scientific Advisory board of AEON Biopharma and serves on the board of directors of Bioniz Therapeutics. He received his M.D. from the University of Miami, FL and his Ph.D. from the University of Cambridge, England.

Bahl and Dr. Carter join a seasoned team of executives who include Steve Johnson (chief operating officer and ex-Allergan vice president), Orest Olejnik (chief scientific officer and ex-SVP Global Pharmaceutical Sciences at Allergan), George Ng (Chief Business officer and ex-president, Business for Scilex Pharmaceuticals) and William Pedranti (Chief Administrative officer and ex-president, Operations for Scilex Pharmaceuticals).

IACTA is an innovation leader in ophthalmic therapeutics, led by former top executives from one of the leading eye care companies in the world. The company currently has four products in development for major market opportunities.

IC 800 is a novel, non-opioid, dual enkephalinase inhibitor, being studied for the treatment of acute ocular pain. In addition, IACTA's IC 265 is a SYK kinase inhibitor being developed as a potential novel treatment for dry eye disease.